Ever Fortune. AI Co. Ltd. announced on the 9th that it has received the medical device approval letter from the U.S. Food and Drug Administration (FDA) for the "Acute Aortic Syndrome Detection System." In total, Ever Fortune has obtained 14 approvals from the Taiwan Food and Drug Administration (TFDA), 10 from the FDA, and eight from other countries, totaling 32 medical device market approvals.
Ever Fortune stated that the "Acute Aortic Syndrome Detection System" developed by the company is a computer-aided triage and notification software (CADt) that utilizes artificial intelligence algorithms and closed-loop deep learning technology to analyze images of thoracic computed tomography (CT) blood vessels to determine whether patients have aortic dissection or intramural hematoma. If the analysis results indicate so, the system will issue an alert to notify healthcare personnel to prioritize manual re-interpretation of blood vessel images, reorder work sequences, or redirect workflow.
Ever Fortune's revenue in the first three months of this year totaled NT$52.87 million, surpassing the total revenue of NT$47.7 million in the first three quarters of last year. Monthly revenue has hit historical highs five times in the past 12 months, with a consecutive nine-month year-on-year growth rate exceeding 10%. Whether in new product development or revenue, Ever Fortune has performed impressively this year.
Resource (Mandarin):
